top of page

EXCAAPE

EVALUATION OF RADIUM-223 ACTIVITY IN ASYMPTOMATIC PATIENTS WITH mCRPC WHILE ON ABIRATERONE OR ENZALUTAMIDE BESIDES AR-V7 STATUS

CLINICAL TRIAL DETAILS

TO EVALUATE RADIOGRAPHIC PROGRESSION-FREE SURVIVAL (rPFS) OF RADIUM-223 (223Ra) FOR THE TREATMENT OF ASYMPTOMATIC METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC) PATIENTS WITH BONE METASTASES AND NO VISCERAL INVOLVEMENT WHO HAD PREVIOUSLY PROGRESSED ON ABIRATERONE ACETATE OR ENZALUTAMIDE.

TUMOR TYPE

PHASE

N

SITES

COUNTRY

STATUS

PRESS RELEASE

home_fondo_you_barra.jpg

SCIENTIFIC IMPACT

home_fondo_you_barra.jpg

BLOG ARTICLES RELATED

home_fondo_you_barra.jpg

PHERGAIN SITES

home_fondo_you_barra.jpg
Hospital Universitario Vall d'Hebron (Spain) | Hospital Clínic de Barcelona (Spain) | Hospital Universitario Ramón y Cajal (Spain) | Hospital Reina Sofía (Spain) | Hospital San Pedro Alcántara (Spain) | Hospital Parc Taulí (Spain) | Instituto Catalán de Oncología de Hospitalet (ICO) (Spain) | Hospital Lucus Augusti (Spain) | Hospital Universitari Son Espases (Spain)
Dr. Cortes and Dr. Llombart PHERain interview
Beyond Chemotherapy
Dr. Vanes Quiroga
Dr. Sofia Braga
Dr. Silvi Antolín
Dr. Escrivá de Romaní
Dr. Philipp Aftimos
Dr. Manuel Ruiz
Prof. Daniele Generali PHEGain interview
Dr. Jacques Medioni
Dr. Dunca Wheatley
bottom of page